Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNektar Therapeutics Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 5 | -$2.62 | -$1.11 | -$1.58 |
| Q2 2026 | 5 | -$2.51 | -$1.24 | -$1.97 |
| Q3 2026 | 6 | -$2.92 | -$1.69 | -$2.13 |
| Q4 2026 | 6 | -$3.39 | -$2.15 | -$2.74 |
| Q1 2027 | 2 | -$3.28 | -$2.61 | -$2.85 |
| Q2 2027 | 2 | -$3.22 | -$2.56 | -$2.80 |
| Q3 2027 | 2 | -$3.47 | -$2.76 | -$3.02 |
| Q4 2027 | 2 | -$3.38 | -$2.68 | -$2.94 |
| Q1 2028 | 5 | -$5.33 | -$4.24 | -$4.64 |
| Q2 2028 | 5 | -$5.15 | -$4.10 | -$4.48 |
| Q3 2028 | 5 | -$4.74 | -$3.77 | -$4.13 |
| Q4 2028 | 5 | -$4.42 | -$3.52 | -$3.85 |
| Q1 2029 | 2 | -$4.06 | -$3.23 | -$3.54 |
| Q2 2029 | 2 | -$4.14 | -$3.29 | -$3.61 |
| Q3 2029 | 2 | -$3.86 | -$3.07 | -$3.36 |
| Q4 2029 | 2 | -$3.88 | -$3.09 | -$3.38 |
Nektar Therapeutics Earnings Date And Information
Nektar Therapeutics last posted its earnings results on Thursday, August 13th, 2026. The company reported $-1.23 earnings per share for the quarter, topping analysts' consensus estimates of $-1.97 by $0.74. The company had revenue of 10.13 M for the quarter and had revenue of 55.23 M for the year. Nektar Therapeutics has generated $-10 earnings per share over the last year ($-9.73 diluted earnings per share) and currently has a price-to-earnings ratio of -9.98. Nektar Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Nektar Therapeutics Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2026 | Q2 2026 | N/A | -$1.23 | N/A | $10.43 M | $10.13 M |
| 05/07/2026 | Q1 2026 | N/A | -$1.82 | N/A | $10.69 M | $10.86 M |
| 03/12/2026 | Q4 2025 | N/A | -$1.78 | N/A | $10.19 M | $21.81 M |
| 11/06/2025 | Q3 2025 | N/A | -$1.87 | N/A | $10.05 M | $11.79 M |
| 08/07/2025 | Q2 2025 | N/A | -$2.95 | N/A | $9.49 M | $11.18 M |
| 05/08/2025 | Q1 2025 | N/A | -$3.62 | N/A | $15.35 M | $10.46 M |
| 03/14/2025 | Q4 2024 | N/A | $0.52 | N/A | $35.50 M | $29.18 M |
| 11/07/2024 | Q3 2024 | N/A | -$2.66 | N/A | $19.18 M | $24.12 M |
| 08/08/2024 | Q2 2024 | N/A | -$3.76 | N/A | $18.20 M | $23.49 M |
| 05/09/2024 | Q1 2024 | N/A | -$2.83 | N/A | $15.34 M | $21.64 M |
| 03/05/2024 | Q4 2023 | N/A | -$3.30 | N/A | $21.43 M | $23.89 M |
| 11/07/2023 | Q3 2023 | N/A | -$3.61 | N/A | $21.26 M | $24.14 M |
| 08/08/2023 | Q2 2023 | N/A | -$4.05 | N/A | $21.79 M | $20.50 M |
| 05/09/2023 | Q1 2023 | N/A | -$10.95 | N/A | $19.41 M | $21.59 M |
| 02/28/2023 | Q4 2022 | -$0.45 | -$4.80 | -4.35 | $22.14 M | $22.02 M |
| 11/04/2022 | Q3 2022 | N/A | -$4.65 | N/A | $22.61 M | $23.63 M |
| 08/04/2022 | Q2 2022 | N/A | -$12.75 | N/A | $22.62 M | $21.59 M |
| 05/05/2022 | Q1 2022 | N/A | -$7.35 | N/A | $24.30 M | $24.82 M |
| 02/28/2022 | Q4 2021 | N/A | -$11.85 | N/A | $34.26 M | $25.01 M |
| 11/04/2021 | Q3 2021 | N/A | -$10.50 | N/A | $28.13 M | $24.92 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Nektar Therapeutics Earnings: FAQ's
In the previous quarter, Nektar Therapeutics (:NKTR) reported $-1.23 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.97 by $0.74.
The conference call for Nektar Therapeutics's latest earnings report can be listened to online.
The conference call transcript for Nektar Therapeutics's latest earnings report can be read online.
Nektar Therapeutics (:NKTR) has a recorded annual revenue of $55.23 M.
Nektar Therapeutics (:NKTR) has a recorded net income of $-164,076,000.Nektar Therapeutics has generated $-9.73 earnings per share over the last four quarters.
Nektar Therapeutics (:NKTR) has a price-to-earnings ratio of -9.98 and price/earnings-to-growth ratio is -1.04.